Determining Actual Death Rate from COVID-19 in the US
by Mohamed Al-Ibrahim, MB ChB, FACP
There is great concern about the effects of COVID-19 in the United States population. Unfortunately, there are no helpful mortality estimates; there is simply no readily useful denominator. We will not get much further until we have accurate numbers for sero-positivity in the general population. This will take months. The sero-positivity in respiratory viral illness is typically >2x that of PCR (Polymerase Chain Reaction).*
The mortality numbers according to the John Hopkins University (JHU) map are literally all over the map and impossible to rely on: Italy 6.8%, Iran 4.8%, and S Korea 0.8%. According to JHU data, as of March 16, 2020, there are now 3,813 confirmed COVID-19 cases in the US and 69 deaths with a mortality of 1.8% (1). Of the 69 deaths, 42 (61%) of the total occurred in Washington State and 27 occurred in King County, WA. Twenty-two of 27 deaths in King County occurred in one nursing home facility in Kirkland. This is unfortunate but not unexpected for infectious disease outbreaks in such facilities and similar to influenza and norovirus gastroenteritis. Thus far, and thanks to poor federal government efforts, we have no idea how many individuals have been tested.
Once testing becomes more available in the next several weeks, an effort should be undertaken in several locations to test as many people as possible for the virus within 25 miles from the epicenter of a known cluster of cases. The deaths in these 25 mile circular regions would be the numerator for a death rate calculation. The number of individuals with positive test results in these regions would be the denominator. The result will be a more accurate estimate of the actual death rate of COVID-19.
*Polymerase chain reaction (PCR) is a method widely used in molecular biology to rapidly make millions to billions of copies of a specific DNA sample allowing scientists to take a very small sample of DNA and amplify it to a large enough amount to study in detail.
Mohamed S. Al-Ibrahim, MB ChB, FACP, is Senior Investigator at Pharmaron CPC in Baltimore, Maryland, and Adjunct Professor of Medicine at the University of Maryland School of Medicine. Dr Al-Ibrahim previously served as President of SNBL Clinical Pharmacology Center Inc. as well as Chief Operating Officer of SNBL from August 2007 to December 2011. He also served as Chief Medical Officer of Maryland General Hospital
- Announcements2021.06.21AcademyHealth Call for Nominations
- Healthy People 20302021.06.16Podcast: Law and Policy as Tools in Healthy People 2030
- HRSA's Investment in Public Health2021.05.18Video Q&A — Preventive Medicine for Rural America: Why More Training Programs Must Be Here
- APHA HA Section2021.05.17Racism Is a Public Health Crisis Policies and COVID-19